Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives
Open accessThe DOI matches its Crossref record; 151 of the 217 references it cites were found in a registry or an index, and 3 are not checked yet.
Abstract
Iron is a micronutrient essential for cellular energy and metabolism, necessary for maintaining body homoeostasis. Iron deficiency is an important co-morbidity in patients with heart failure (HF). A major factor in the pathogenesis of anaemia, it is also a separate condition with serious clinical consequences (e.g. impaired exercise capacity) and poor prognosis in HF patients. Experimental evidence suggests that iron therapy in iron-deficient animals may activate molecular pathways that can be cardio-protective. Clinical studies have demonstrated favourable effects of i.v. iron on the functional status, quality of life, and exercise capacity in HF patients. It is hypothesized that i.v. iron supplementation may become a novel therapy in HF patients with iron deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The definition of ID in general may also play a role because some studies only use ferritin levels <100 μg/mL as definition of ID whereas others also take a low transferrin saturation into account”
From Anaemia, iron status, and gender predict the outcome in patients with chronic heart failure (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“and linked to an increased mortality. 12 , 13”
From Anaemia, iron status, and gender predict the outcome in patients with chronic heart failure (2020) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“because the latter parameter reflects iron availability for the bone marrow and tissue. 12 , 13 , 14 , 15”
From Anaemia, iron status, and gender predict the outcome in patients with chronic heart failure (2020) · cites this paper as [12]
In the citing paper
“This appears to be in contrast to recent studies, 12 , 13 where ID was an even stronger predictor of mortality than anaemia without ID.”
From Anaemia, iron status, and gender predict the outcome in patients with chronic heart failure (2020) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maternal and child undernutrition: global and regional exposures and health consequences
Black, R. E., Allen, L. H., Bhutta, Z. A., Caulfield, L. E., de Onis, M., Ezzati, M., Mathers, C., & Rivera, J. (2008) · The Lancet · doi:10.1016/s0140-6736(07)61690-0 · Cited by 6,443
(2015) · American Journal Of Pathology · doi:10.2353/ajpath · Cited by 4,908
Andrews, N. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912233412607 · Cited by 2,130 · cited 5×
“–34,37,38 Cells with a high mitogenic potential (neoplastic, haematopoietic, immune) and high-energy demand (hepatocytes, adipocytes, skeletal and cardiac myocytes, renal cells) are particularly sensitive to depleted iron supplies and/or abnormal iron utilization.(1,3,32,35,37) This is important in HF, as abnormal ene…”
BackgroundInfluentialTwo to tango: Regulation of Mammalian iron metabolism
Hentze, M. W., Muckenthaler, M. U., Galy, B., & Camaschella, C. (2010) · Cell · doi:10.1016/j.cell.2010.06.028 · Cited by 2,120 · cited 5×
“It is present on virtually all cells, but a vast majority is localized on erythroid precursors.(57,90) When iron delivery to target tissues is insufficient for metabolic requirements, the expression of the transferrin receptor increases in order to facilitate intracellular iron influx.”
BackgroundInfluentialFerric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
Anker, S. D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., Lüscher, T. F., Bart, B., Banasiak, W., Niegowska, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908355 · Cited by 2,083
Regulatory T cells mediate maternal tolerance to the fetus
Aluvihare, V. R., Kallikourdis, M., & Betz, A. G. (2004) · Nature Immunology · doi:10.1038/ni1037 · Cited by 1,657
REVIEW ARTICLE: The Immune System in Pregnancy: A Unique Complexity
Mor, G., & Cardenas, I. (2010) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2010.00836.x · Cited by 1,431
Zimmermann, M. B., & Hurrell, R. F. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61235-5 · Cited by 1,405
Haas, J. D., & Brownlie, T. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.2.676s · Cited by 1,186
Iron Biology in Immune Function, Muscle Metabolism and Neuronal Functioning
Beard, J. L. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.2.568s · Cited by 1,134 · cited 1×
“–34,37,38 Cells with a high mitogenic potential (neoplastic, haematopoietic, immune) and high-energy demand (hepatocytes, adipocytes, skeletal and cardiac myocytes, renal cells) are particularly sensitive to depleted iron supplies and/or abnormal iron utilization.(1,3,32,35,37) This is important in HF, as abnormal ene…”
Background
Research works printed but not linked: 16
- 2009, American Journal of Physiology - Heart and Circulatory Physiology, 296, H585, 10.1152/ajpheart.00463.2008 · DOI · Paper page
- 2005, Clinical science, 109, 277, 10.1042/CS20040278 · DOI · Paper page
- 2006, Journal of the American College of Cardiology, 48, 2485, 10.1016/j.jacc.2006.08.034 · DOI · Paper page
- 2007, Journal of the American College of Cardiology, 49, 753, 10.1016/j.jacc.2006.11.024 · DOI · Paper page
- 2009, Cardiovascular Research, 81, 412, 10.1093/cvr/cvn301 · DOI · Paper page
- 2010, Cardiovascular Research, 88, 40, 10.1093/cvr/cvq240 · DOI · Paper page
- 2011, Journal of Pharmacology and Experimental Therapeutics, 336, 56, 10.1124/jpet.110.172668 · DOI
- 2003, ASH Education Program Book, 1, 40
- 2011, Journal of Clinical Pathology, 64, 281, 10.1136/jcp.2010.079046 · DOI · Paper page
- 2009, ASH Education Program Book, 1, 207
- 2007, Journal of the American College of Cardiology, 50, 40, 10.1016/j.jacc.2007.02.067 · DOI · Paper page
- 2006, Cardiovascular Research, 70, 434, 10.1016/j.cardiores.2006.01.013 · DOI
- 2007, Journal of the American College of Cardiology, 50, 1657, 10.1016/j.jacc.2007.07.029 · DOI · Paper page
- 2006, Journal of the American College of Cardiology, 48, 1225, 10.1016/j.jacc.2006.07.015 · DOI · Paper page
- 1981, American Journal of Physiology - Gastrointestinal and Liver Physiology, 241, C47
- 1982, American Journal of Physiology - Gastrointestinal and Liver Physiology, 242, E418
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Self-citation2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
“Iron deficiency is common in HF, as it is with other chronic illnesses, and it can lead to anaemia and/or skeletal muscle dysfunction without anaemia.(466) Within an HF population, iron deficiency is associated with a worse prognosis.”
Ponikowski, P., Kirwan, B.-A., Anker, S. D., McDonagh, T., Dorobantu, M., Drozdz, J., Fabien, V., Filippatos, G., Göhring, U. M., Keren, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32339-4 · Cited by 795
Ezekowitz, J. A., O'Meara, E., McDonald, M. A., Abrams, H., Chan, M., Ducharme, A., Giannetti, N., Grzeslo, A., Hamilton, P. G., Heckman, G. A., et al. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.08.022 · Cited by 676
Iron deficiency anaemia revisited
Cappellini, M. D., Musallam, K. M., & Taher, A. T. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13004 · Cited by 508
Cappellini, M. D., Comin‐Colet, J., de Francisco, A., Dignass, A., Doehner, W., Lam, C. S., Macdougall, I. C., Rogler, G., Camaschella, C., Kadir, R., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24820 · Cited by 502
“antiplatelet and anticoagulant drugs; and, importantly, as a consequence of the chronic inflammatory state of these patients.(28,39) The”
BackgroundSelf-citation2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0141 · Cited by 444
van Veldhuisen, D. J., Ponikowski, P., van der Meer, P., Metra, M., Böhm, M., Doletsky, A., Voors, A. A., Macdougall, I. C., Anker, S. D., Roubert, B., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.027497 · Cited by 423
Anker, S. D., Kirwan, B.-A., van Veldhuisen, D. J., Filippatos, G., Comin-Colet, J., Ruschitzka, F., Lüscher, T. F., Arutyunov, G. P., Motro, M., Mori, C., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.823 · Cited by 412
2020 Clinical practice guidelines for Chronic heart failure
Russian Society of Cardiology (RSC) (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-4083 · Cited by 395
Jankowska, E. A., Tkaczyszyn, M., Suchocki, T., Drozd, M., von Haehling, S., Doehner, W., Banasiak, W., Filippatos, G., Anker, S. D., & Ponikowski, P. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.473 · Cited by 346
Hoes, M. F., Grote Beverborg, N., Kijlstra, J. D., Kuipers, J., Swinkels, D. W., Giepmans, B. N. G., Rodenburg, R. J., van Veldhuisen, D. J., de Boer, R. A., & van der Meer, P. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1154 · Cited by 333
Iron deficiency and cardiovascular disease
von Haehling, S., Jankowska, E. A., van Veldhuisen, D. J., Ponikowski, P., & Anker, S. D. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.109 · Cited by 306
Iron Deficiency in Heart Failure
von Haehling, S., Ebner, N., Evertz, R., Ponikowski, P., & Anker, S. D. (2019) · JACC: Heart Failure · doi:10.1016/j.jchf.2018.07.015 · Cited by 304
“Because no means of iron excretion exists, only the uptake in the duodenum and the upper jejunum is regulated (20).”
BackgroundThe Clinical Significance of Interleukin-6 in Heart Failure: Results from the BIOSTAT-CHF Study
Markousis-Mavrogenis, G., Tromp, J., Ouwerkerk, W., Devalaraja, M., Anker, S. D., Cleland, J. G., Dickstein, K., Filippatos, G. S., van der Harst, P., Lang, C. C., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1482 · Cited by 294
Iron status in patients with chronic heart failure
Jankowska, E. A., Malyszko, J., Ardehali, H., Koc-Zorawska, E., Banasiak, W., von Haehling, S., Macdougall, I. C., Weiss, G., McMurray, J. J. V., Anker, S. D., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs377 · Cited by 273
Ferric Carboxymaltose in Heart Failure with Iron Deficiency
Mentz, R. J., Garg, J., Rockhold, F. W., Butler, J., De Pasquale, C. G., Ezekowitz, J. A., Lewis, G. D., O’Meara, E., Ponikowski, P., Troughton, R. W., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304968 · Cited by 251
Jankowska, E. A., Kasztura, M., Sokolski, M., Bronisz, M., Nawrocka, S., Ole kowska-Florek, W., Zymli ski, R., Biegus, J., Siwo owski, P., Banasiak, W., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu235 · Cited by 242
Myocardial Iron Content and Mitochondrial Function in Human Heart Failure: A Direct Tissue Analysis
Melenovsky, V., Petrak, J., Mracek, T., Benes, J., Borlaug, B. A., Nuskova, H., Pluhacek, T., Spatenka, J., Kovalcikova, J., Drahota, Z., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.640 · Cited by 231
Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure
Njoroge, J. N., & Teerlink, J. R. (2021) · Circulation Research · doi:10.1161/circresaha.121.318186 · Cited by 214
2024 Clinical practice guidelines for Chronic heart failure
Galyavich, A. S., Tereshchenko, S. N., Uskach, T. M., Ageev, F. T., Aronov, D. M., Arutyunov, G. P., Begrambekova, Y. L., Belenkov, Y. N., Boytsov, S. A., Bubnova, M. G., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6162 · Cited by 204
Martens, P., Nijst, P., Verbrugge, F. H., Smeets, K., Dupont, M., & Mullens, W. (2018) · Acta Cardiologica · doi:10.1080/00015385.2017.1351239 · Cited by 181
“Indeed, iron deficiency can cause anaemia, but also reduces myoglobin content and mitochondrial respiratory chain proteins, hereby limiting the peripheral extraction of O2 (the difference between arterial and venous O2 content) [14].”
BackgroundRole of iron metabolism in heart failure: From iron deficiency to iron overload
Zhang, H., Zhabyeyev, P., Wang, S., & Oudit, G. Y. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.08.030 · Cited by 181
Mechanisms Linking Red Blood Cell Disorders and Cardiovascular Diseases
Mozos, I. (2015) · BioMed Research International · doi:10.1155/2015/682054 · Cited by 139
Prevalence and Outcomes of Anemia and Hematinic Deficiencies in Patients With Chronic Heart Failure
Cleland, J. G. F., Zhang, J., Pellicori, P., Dicken, B., Dierckx, R., Shoaib, A., Wong, K., Rigby, A., Goode, K., & Clark, A. L. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.1161 · Cited by 175
“In 2008, the European Society of Cardiology guidelines indicated that a diagnosis of HF was unlikely if the plasma NT-proBNP concentration was less than 400 pg/mL (to convert to nanograms per liter, multiply by 1).12 Accordingly, patients were assigned to 1 of the following 5 cardiac phenotypes based on echocardiograp…”
MethodTrace minerals intake: Risks and benefits for cardiovascular health
Mohammadifard, N., Humphries, K. H., Gotay, C., Mena-Sánchez, G., Salas-Salvadó, J., Esmaillzadeh, A., Ignaszewski, A., & Sarrafzadegan, N. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2017.1406332 · Cited by 167
Anemia and iron deficiency in gastrointestinal and liver conditions
Stein, J. M., Connor, S. J., Virgin, G., Ong, D. E. H., & Pereyra, L. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i35.7908 · Cited by 194
The Burden of Iron Deficiency in Heart Failure
Rocha, B. M. L., Cunha, G., & Falcão, L. F. D. M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.12.027 · Cited by 187
Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology
Alnuwaysir, R. I. S., Hoes, M. F., van Veldhuisen, D. J., van der Meer, P., & Beverborg, N. G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm11010125 · Cited by 198
“Accordingly, these cells are more sensitive to ID [26].”
BackgroundInfluentialLanser, L., Fuchs, D., Kurz, K., & Weiß, G. (2021) · Nutrients · doi:10.3390/nu13113732 · Cited by 211
“Elevated serum concentrations of neopterin were associated with a poor outcome and anemia in patients with cancer [25,190], CAD [16], CHF [191] and pulmonary disease [192,193].”
BackgroundInfluentialMore than a simple biomarker: the role of NGAL in cardiovascular and renal diseases
Buonafine, M., Martínez‐Martínez, E., & Jaisser, F. (2018) · Clinical Science · doi:10.1042/cs20171592 · Cited by 180
“Both iron overload and iron deficiency have been linked to cardiomyopathies: iron overload has been associated with increased oxidative stress and iron deficiency with mitochondrial dysfunction, impaired cardiac function (98), hyper-coagulation and oxidative”
BackgroundIron Therapy for the Treatment of Iron Deficiency in Chronic Heart Failure: Intravenous or Oral?
McDonagh, T., & Macdougall, I. C. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.236 · Cited by 149
Yeo, T. J., Yeo, P. S. D., Ching-Chiew Wong, R., Ong, H. Y., Leong, K. T. G., Jaufeerally, F., Sim, D., Santhanakrishnan, R., Lim, S. L., Chan, M. M. Y., et al. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.161 · Cited by 141
Heart Failure With Preserved Ejection Fraction: A Review of Cardiac and Noncardiac Pathophysiology
Gevaert, A. B., Boen, J. R. A., Segers, V. F. M., & Craenenbroeck, E. M. V. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00638 · Cited by 154
“Additionally, angiotensin II and aldosterone induce extracellular fibrosis through direct stimulation of collagen secretion by myofibroblasts, nicotinamide adenine dinucleotide phosphate oxidase activation, and suppression of matrix metalloproteinases (Murdoch et al., 2014; Jia et al., 2018).”
BackgroundEbner, N., Jankowska, E. A., Ponikowski, P., Lainscak, M., Elsner, S., Sliziuk, V., Steinbeck, L., Kube, J., Bekfani, T., Scherbakov, N., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.11.178 · Cited by 131
Self-citationCotroneo, E., Ashek, A., Wang, L., Wharton, J., Dubois, O., Bozorgi, S., Busbridge, M., Alavian, K. N., Wilkins, M. R., & Zhao, L. (2015) · Circulation Research · doi:10.1161/circresaha.116.305265 · Cited by 142
McDonagh, T., Damy, T., Doehner, W., Lam, C. S. P., Sindone, A., van der Meer, P., Cohen-Solal, A., Kindermann, I., Manito, N., Pfister, O., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1305 · Cited by 121
Taniguchi, R., Kato, H. E., Font, J., Deshpande, C. N., Wada, M., Ito, K., Ishitani, R., Jormakka, M., & Nureki, O. (2015) · Nature Communications · doi:10.1038/ncomms9545 · Cited by 120
Impact Analysis of Heart Failure Across European Countries: An ESC-HFA Position Paper
Rosano, G. M. C., Seferovic, P. M., Savarese, G., Spoletini, I., Lopatin, Y. M., Gustafsson, F., Bayés‐Genís, A., Jaarsma, T., Abdelhamid, M., González, A., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14076 · Cited by 132
“%) were also very common.48,49 These conditions not only impact the pathophysiological progression of HF but also limit the initiation and titration of evidence-based drug and diuretic therapy, leading to increased risk of hospitalization and a large impact on healthcare systems expenditures.50 In particular, iron def…”
Backgroundvan der Wal, H. H., Beverborg, N. G., Dickstein, K., Anker, S. D., Lang, C. C., Ng, L. L., van Veldhuisen, D. J., Voors, A. A., & van der Meer, P. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz680 · Cited by 120
“Suggested mechanisms for ID in HF are poor dietary iron intake, drug interactions, (occult) gastrointestinal blood loss due to antiplatelet drugs and anticoagulants, and hepcidin-induced iron entrapment due to chronic lowgrade inflammation.(5) While ID is present in approximately half of all HF patients, its prevalenc…”
BackgroundFranceschi, L. D., Iolascon, A., Taher, A. T., & Cappellini, M. D. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.04.018 · Cited by 126
Silverberg, D. S., Mor, R., Weu, M. T., Schwartz, D., Schwartz, I. F., & Chernin, G. (2014) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-14-24 · Cited by 113
“Several definitions for ID were suggested [23] and here we defined ID by three different criteria: (i) serum ferritin of <100 ng/ml, (ii) %TSat <20%, or (iii) either a serum ferritin of <100 ng/ml or the combination of serum ferritin of 100-300 ng/ml and %TSat of <20%.”
MethodFerritin Levels and Risk of Heart Failure—the Atherosclerosis Risk in Communities Study
Silvestre, O. M., Gonçalves, A., Nadruz, W., Claggett, B. L., Couper, D. J., Eckfeldt, J. H., Pankow, J. S., Anker, S. D., & Solomon, S. D. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.701 · Cited by 92
2020 Clinical practice guidelines for Chronic heart failure
Russian Society of Cardiology (2020) · Russian Journal of Cardiology · doi:10.15829/29/1560-4071-2020-4083 · Cited by 88
Toblli, J. E., Gennaro, F. D., & Rivas, C. (2015) · Heart Lung and Circulation · doi:10.1016/j.hlc.2014.12.161 · Cited by 98
“CHF is associated, in a variable degree, to iron-deficient erythropoiesis by the action of inflammatory cytokines that promote hepcidin production, which in turn blocks gastrointestinal iron absorption and also impairs its release from the reticuloendothelial system [4-6].”
BackgroundGhafourian, K., Shapiro, J. S., Goodman, L., & Ardehali, H. (2020) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.08.009 · Cited by 106
“However, recent studies in chronic as well as acute HF demonstrated the opposite and showed that the serum hepcidin level is actually diminished in HF (21,32).”
BackgroundSierpinski, R., Josiak, K., Suchocki, T., Wojtas‐Polc, K., Mazur, G., Butrym, A., Rozentryt, P., van der Meer, P., Comin‐Colet, J., von Haehling, S., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2036 · Cited by 82
Iron Status and Survival in Diabetic Patients With Coronary Artery Disease
Ponikowska, B., Suchocki, T., Paleczny, B., Olesińska‐Mader, M., Powierza, S., Borodulin-Nadzieja, L., Reczuch, K. W., von Haehling, S., Doehner, W., Anker, S. D., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0528 · Cited by 90
“The physiological significance of ID may be much broader than its role in erythropoiesis (1,7,11,12).”
BackgroundRodrigues, D., Freitas, A. C., Rocha‐Santos, T., Vasconcelos, M. W., Roriz, M., Rodríguez-Alcalá, L. M., Gomes, A., & Duarte, A. C. (2015) · Journal of Food Science and Technology · doi:10.1007/s13197-015-1826-z · Cited by 91
“Iron is known to be essential for cellular energy and metabolism (Jankowska et al. 2013) and its deficiency is associated to anaemia which affect adversely patients with chronic heart disease (Comín-Colet et al.”
BackgroundAnaemia, iron status, and gender predict the outcome in patients with chronic heart failure
Kurz*†, K., Lanser†, L., Seifert, M., Kocher, F., Pölzl, G., & Weiss*, G. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12755 · Cited by 77
“In both cases, iron availability for erythropoiesis is limited resulting in the development of anaemia over time.14,15 The aetiology of anaemia in CHF is often unclear, but inflammation might be a central underlying component because immune activation and increased circulating cytokine levels are observed in patients…”
BackgroundInfluentialIron status in the elderly: A review of recent evidence
Wawer, A. A., Jennings, A., & Fairweather‐Tait, S. J. (2018) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2018.07.003 · Cited by 94
Moliner, P., Jankowska, E. A., van Veldhuisen, D. J., Farre, N., Rozentryt, P., Enjuanes, C., Polonski, L., Meroño, O., Voors, A. A., Ponikowski, P., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.04.110 · Cited by 67
Iron Deficiency in Heart Failure: A Scientific Statement from the Heart Failure Society of America
Beavers, C. J., Ambrosy, A. P., Butler, J., Davidson, B. T., Gale, S. E., Piña, I. L., Mastoris, I., Reza, N., Mentz, R. J., & Lewis, G. D. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.03.025 · Cited by 90
Iron Deficiency and Red Cell Indices in Patients with Heart Failure
Tkaczyszyn, M., Colet, J. C., Voors, A. A., van Veldhuisen, D. J., Enjuanes, C., Moliner, P., Rozentryt, P., Poloński, L., Banasiak, W., Ponikowski, P. P., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.820 · Cited by 90
Steinbeck, L., Ebner, N., Valentová, M., Bekfani, T., Elsner, S., Dahinden, P., Hettwer, S., Scherbakov, N., Schefold, J. C., Sandek, A., et al. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.400 · Cited by 76
Anemia of Inflammation with An Emphasis on Chronic Kidney Disease
Begum, S., & Latunde-Dada, G. O. (2019) · Nutrients · doi:10.3390/nu11102424 · Cited by 91
“In the anemic patients, 62% had absolute iron deficiency, while FID was 10% [37].”
BackgroundInfluentialEnjuanes, C., Bruguera, J., Grau, M., Cladellas, M., González, G., Meroño, O., Moliner, P., Verdú-Rotellar, J. M., Farré, N., & Colet, J. C. (2015) · Revista Española de Cardiología · doi:10.1016/j.recesp.2015.08.017 · Cited by 74
Iron induces insulin resistance in cardiomyocytes via regulation of oxidative stress
Sung, H. K., Song, E., Jahng, J. W. S., Pantopoulos, K., & Sweeney, G. (2019) · Scientific Reports · doi:10.1038/s41598-019-41111-6 · Cited by 82
Becher, P. M., Schrage, B., Benson, L., Fudim, M., Cabrera, C. C., Dahlström, U., Rosano, G. M. C., Jankowska, E. A., Anker, S. D., Lund, L. H., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2338 · Cited by 74
Myocardial Iron Deficiency and Mitochondrial Dysfunction in Advanced Heart Failure in Humans
Zhang, H., Jamieson, K. L., Grenier, J. G., Nikhanj, A., Tang, Z., Wang, F., Wang, S., Seidman, J. G., Seidman, C. E., Thompson, R. B., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.022853 · Cited by 81
“8,45,48 However, the primary determinant of the myocardial iron levels in failing human hearts remains unexplored.”
Adverse Outcome Prediction of Iron Deficiency in Patients with Acute Coronary Syndrome
Zeller, T., Waldeyer, C., Ojeda, F., Schnabel, R. B., Schäfer, S., Altay, A., Lackner, K. J., Anker, S. D., Westermann, D., Blankenberg, S., et al. (2018) · Biomolecules · doi:10.3390/biom8030060 · Cited by 69
“Moreover, iron is essential for cardiac and skeletal muscle metabolism, the synthesis and degradation of proteins, lipids, ribonucleic acids, and mitochondrial function [3].”
BackgroundIron Deficiency in Chronic Heart Failure: Case-Based Practical Guidance
Lam, C. S. P., Doehner, W., & Colet, J. C. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12333 · Cited by 72
“occur with iron homeostasis mechanisms and erythropoiesis still intact.(6,21)”
BackgroundInfluentialSkeletal Muscle Abnormalities and Iron Deficiency in Chronic Heart Failure
Melenovský, V., Hlavatá, K., Šedivý, P., Dezortová, M., Borlaug, B. A., Petrák, J., Kautzner, J., & Hájek, M. (2018) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.004800 · Cited by 71
Bömer, N., Pávez, M., Beverborg, N. G., Cleland, J. G. F., van Veldhuisen, D. J., & van der Meer, P. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13456 · Cited by 70
Cheng, C., Huang, D., Zhao, L., Cao, C., & Chen, G. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.04.015 · Cited by 63
Enjuanes, C., Bruguera, J., Grau, M., Cladellas, M., González, G., Meroño, O., Moliner, P., Verdú-Rotellar, J. M., Farré, N., & Colet, J. C. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2015.08.018 · Cited by 81
“Some authors support the hypothesis that ID may be behind mitochondrial dysfunction.(29) Additionally, and in support of this hypothesis, there is evidence on the effect of intravenous iron supplementation on ID anemic and nonanemic patients with CHF, increasing 6MWT distance, and improving functional capacity (NYHA f…”
BackgroundComorbidities in Heart Failure
van der Wal, H. H., van Deursen, V. M., van der Meer, P., & Voors, A. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_27 · Cited by 74
Anemia in heart failure - from guidelines to controversies and challenges
Sîrbu, O., Floria, M., Dăscălița, P., Stoica, A., Adascalitei, P., Șorodoc, V., & Șorodoc, L. (2018) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2018.08634 · Cited by 75
“Whether the conclusions apply to patients with HF is yet to be determined (5).”
BackgroundManagement of anemia in patients with congestive heart failure
Tim Goodnough, L., Comin‐Colet, J., Leal‐Noval, S., Ozawa, S., Takere, J., Henry, D., Javidroozi, M., Hohmuth, B., Bisbe, E., Gross, I., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24595 · Cited by 58
“Overall, the evidence for the relative merits of oral versus intravenous iron, has been evolving, and now suggests that prompt intervention using IV iron therapy should now be considered [60,61].”
BackgroundQian, C., Wei, B., Ding, J., Wu, H., & Wang, Y. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.06.009 · Cited by 63
“But when ferritin is between 100 and 300 ng/ mL, the diagnosis of ID is complex and only functional ID can be diagnosed (with TSAT < 20%).(37) Definitions concerning absolute and functional ID should thus be combined, which has been applied in 3 late trials we included.”
Chung, Y. J., Luo, A., Park, K. C., Loonat, A. A., Lakhal‐Littleton, S., Robbins, P. A., & Swietach, P. (2019) · JCI Insight · doi:10.1172/jci.insight.125618 · Cited by 58
Iron deficiency for prognosis in acute coronary syndrome – A systematic review and meta-analysis
Reinhold, J., Papadopoulou, C., Baral, R., & Vassiliou, V. S. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.12.021 · Cited by 56
Ponikowski, P. P., Kirwan, B., Anker, S. D., Dorobanţu, M., Dróżdż, J., Fabien, V., Filippatos, G. S., Haboubi, T., Keren, A., Khintibidze, I., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1710 · Cited by 58
An Etiologic Profile of Anemia in 405 Geriatric Patients
Geisel, T., Martin, J., Schulze, B., Schaefer, R. M., Bach, M., Virgin, G., & Stein, J. M. (2014) · Anemia · doi:10.1155/2014/932486 · Cited by 67
“Conclusive evidence from a large number of studies has confirmed that adequate treatment of iron deficiency significantly improves rates of mortality and morbidity in patients suffering from a wide range of conditions, including chronic heart failure [29, 30], coronary heart disease [31], chronic kidney disease [32, 3…”
BackgroundStructural and functional abnormalities in iron-depleted heart
Kobak, K. A., Radwańska, M., Dzięgała, M., Kasztura, M., Josiak, K., Banasiak, W., Ponikowski, P. P., & Jankowska, E. A. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9738-4 · Cited by 55
Mitochondrial membrane transporters and metabolic switch in heart failure
Kumar, V., Kumar, T. R. S., & Kartha, C. S. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9756-2 · Cited by 53
Correale, M., Paolillo, S., Mercurio, V., Limongelli, G., Barillà, F., Ruocco, G. M., Palazzuoli, A., Scrutinio, D., Lagioia, R., Lombardi, C., et al. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.10.008 · Cited by 59
Iron Deficiency in Heart Failure: A Practical Guide
Ebner, N., & von Haehling, S. (2013) · Nutrients · doi:10.3390/nu5093730 · Cited by 57
“to be an independent risk factor for mortality in HF [3,5].”
BackgroundAnemia and Heart Failure: A Narrative Review
Siddiqui, S. W., Ashok, T., Patni, N., Fatima, M., Lamis, A., & Anne, K. K. (2022) · Cureus · doi:10.7759/cureus.27167 · Cited by 72
“Additionally, the guidelines also recommend the inclusion of iron status as part of the routine follow-up and post-discharge [41,42].”
BackgroundDrozd, M., Jankowska, E. A., Banasiak, W., & Ponikowski, P. P. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0211-2 · Cited by 56
“HF), when diagnosing ID, higher cut-off values of ferritin should be used (100 lg/L) [15, 30, 42].”
BackgroundMethodInfluentialIron Deficiency in Heart Failure: Looking Beyond Anaemia
Wong, C. C. Y., Ng, A. C. C., Kritharides, L., & Sindone, A. P. (2015) · Heart Lung and Circulation · doi:10.1016/j.hlc.2015.06.827 · Cited by 53
“Iron is stored in the liver, spleen, and bone marrow as ferritin [5–9].”
BackgroundInfluentialBone marrow iron depletion is common in patients with coronary artery disease
Jankowska, E. A., Wojtas, K., Kasztura, M., Mazur, G. J., Butrym, A. K., Kalicińska, E., Rybińska, I., Skiba, J., von Haehling, S., Doehner, W., et al. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.10.006 · Cited by 50
“However, low-grade inflammation commonly accompanies cardiovascular diseases, which may modify the production of several markers of ID, reducing their sensitivity and reliability to detect ID (15,21,22).”
BackgroundTkaczyszyn, M., Drozd, M., Węgrzynowska‐Teodorczyk, K., Flinta, I., Kobak, K. A., Banasiak, W., Ponikowski, P. P., & Jankowska, E. A. (2018) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12282 · Cited by 49
“Apart from serum ferritin level, which is a reliable surrogate of total iron stores, similar associations were observed for CHR (even after adjustment for Hb), which is another indicator of iron restriction.(8) Being the key component of oxidative enzymes and respiratory chain proteins within the mitochondria, iron pl…”
BackgroundMethodInfluentialLindberg, F., Lund, L. H., Benson, L., Linde, C. M., Orsini, N., Carrero, J. J., & Savarese, G. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2879 · Cited by 52
Mentz, R. J., Ambrosy, A. P., Ezekowitz, J. A., Lewis, G. D., Butler, J., Wong, Y. W., Pasquale, C. G. D., Troughton, R. W., O’Meara, E., Rockhold, F. W., et al. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.008100 · Cited by 46
Micronutrient Depletion in Heart Failure: Common, Clinically Relevant and Treatable
Cvetinovic, N., Loncar, G., Isakovic, A. M., von Haehling, S., Doehner, W., Lainščak, M., & Farkaš, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225627 · Cited by 45
Prognostic role of transferrin saturation in heart failure patients
Campodonico, J., Nicoli, F., Motta, I., Amicis, M. M. D., Bonomi, A., Cappellini, M. D., & Agostoni, P. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa112 · Cited by 44
Is Correction of Iron Deficiency a New Addition to the Treatment of the Heart Failure?
Silverberg, D. S., Wexler, D., & Schwartz, D. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160614056 · Cited by 46
“The role of iron deficiency (ID) in heart failure (HF) has been the subject of many recent reviews over the last 2 years [1–8].”
BackgroundInfluentialWienbergen, H., Pfister, O., Hochadel, M., Michel, S., Bruder, O., Remppis, B. A., Maeder, M. T., Strasser, R. H., von Scheidt, W., Pauschinger, M., et al. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.08.081 · Cited by 44
Beattie, J. M., Khatib, R., Phillips, C. J., & Williams, S. G. (2020) · Open Heart · doi:10.1136/openhrt-2019-001153 · Cited by 48
“24 HF patients may exhibit absolute or functional ID, the former reflecting depleted iron stores.”
BackgroundIron Therapy in Heart Failure: Ready for Primetime?
Mordi, I. R., Tee, A., & Lang, C. C. (2018) · Cardiac failure review · doi:10.15420/cfr.2018:6:2 · Cited by 42
“Iron is described as either stored (as ferritin within the liver, bone marrow and spleen) or utilised (circulating and intracellular iron).(7) Circulating iron is bound to transferrin, which delivers iron to tissues for utilisation or storage,”
BackgroundHuang, C., Chang, C., Kuo, C., Huang, C., Chiu, T.-W., Lin, C., & Liu, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104495 · Cited by 40
“Treatment with intravenous iron can improve the symptoms of CHF in patients with reduced LV ejection fraction even in the absence of anemia [2].”
BackgroundInfluentialImpact of Iron Deficiency on Response to and Remodeling After Cardiac Resynchronization Therapy
Martens, P., Verbrugge, F. H., Nijst, P., Dupont, M., Tang, W. H. W., & Müllens, W. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.09.017 · Cited by 41
“Its reported prevalence ranges from 16% to 57% depending on the criteria used and population being studied.(16) Because of the guidelinedirected selection of CRT candidates, the present study included patients with symptomatic and advanced HFrEF.”
BackgroundAnemia in severe heart failure patients: does it predict prognosis?
Abebe, T. B., Gebreyohannes, E. A., Bhagavathula, A. S., Tefera, Y. G., & Abegaz, T. M. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0680-5 · Cited by 43
Iron deficiency in patients with heart failure
Fitzsimons, S., & Doughty, R. N. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvu016 · Cited by 44
Cosentino, N., Campodonico, J., Pontone, G., Guglielmo, M., Trinei, M., Sandri, M. T., Riggio, D., Baggiano, A., Milazzo, V., Moltrasio, M., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.07.083 · Cited by 42
Kang, J., Park, J., Lee, J. M., Park, J. J., & Choi, D. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.187 · Cited by 39
Iron deficiency in chronic and acute heart failure: A contemporary review on intertwined conditions
Cunha, G., Rocha, B. M. L., & Falcão, L. M. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.04.013 · Cited by 36
Niehaus, E. D., Malhotra, R. K., Cocca-Spofford, D., Semigran, M. J., & Lewis, G. D. (2015) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2015.05.006 · Cited by 35
Metadata
- Authors
- Jankowska, E. A., von Haehling, S., Anker, S. D., Macdougall, I. C., & Ponikowski, P.
- Affiliations
- Wroclaw Medical University (PL)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- King's College Hospital (GB)
- Corresponding author
- Jankowska, E. A.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-10-25
- Volume
- 34
- Issue
- 11
- Pages
- 816-829
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- PMC
- PMC3596759
- OpenAlex
- W2106650542
- Cited by
- 399
- References
- 152
- Citations by year
- 2026: 13 · 2025: 23 · 2024: 33 · 2023: 30 · 2022: 29 · 2021: 47 · 2020: 32 · 2019: 38 · 2018: 34 · 2017: 32 · 2016: 31 · 2015: 33 · 2014: 17 · 2013: 6 · 2012: 1
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- European Heart Journal (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, other-oa)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- iron deficiency, heart failure, iron deficiency anemia, intravenous iron, iron supplementation, exercise capacity, prognosis, micronutrients
- MeSH terms
- Iron Deficiencies, Depression, Diagnosis, Differential, Heart Failure, Humans, Iron, Muscular Diseases, Cardiomyopathies, Prognosis, Exercise Tolerance, Iron, Dietary, Dietary Supplements
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.